Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Countdown to Merck (MRK) Q4 Earnings: Wall Street Forecasts for Key Metrics

Fiverr

Merck is well on its way to replacing its most important growth driver. Fiverr will continue to benefit from the expanding gig economy.

A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years

Johnson & Johnson

Bristol-Myers

Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.

Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Reduced the Risk of Death Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy.

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.

Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices

AbbVie

Healthcare had a mediocre performance in 2023, but it remains a suitable addition to a diversified portfolio due to its defensive characteristics. AbbVie Inc. and Merck & Co., Inc. are attractive healthcare players that also provide steady dividends and potential for growth. AbbVie is navigating the Humira patent cliff and expects to return to earnings growth in 2025, while Merck's Keytruda is driving sales but faces competition with a patent expiration in 2028.

AbbVie And Merck: Defensive Healthcare Plays Providing Income

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Significantly Improved DFS as Adjuvant Therapy in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced UC.

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

VANCOUVER, British Columbia--(BUSINESS WIRE)--Merck and Variational AI apply generative AI-powered foundation model for drug discovery.

Variational AI Announces Generative AI Project With Merck

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.

Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Second-Quarter 2024 Dividend.

Merck Announces Second-Quarter 2024 Dividend

Merck plans to buy biotech Harpoon Therapeutics. Harpoon's platform is powerful, and it could produce many opportunities.

This 1 Bullish Move by Merck Could Drive Growth for Years to Come

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1.

Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1

Assurant

Entergy

Coca-Cola

McDonald's

Mondelez

Procter & Gamble

One way for investors to hedge during broad-market downturns is with low-volatility stocks. Here are seven to consider.

7 Best Low-Volatility Stocks to Buy

AstraZeneca

Gilead Sciences

By Feb. 1, the federal government will send an initial offer for each of the 10 drugs selected for the first round of negotiations under the program, which was established under the Inflation Reduction Act and touted by President Joe Biden as part of a broader effort to drive down healthcare costs. Yet several lawsuits challenging the program could also reach turning points in the coming months, raising the prospect that some elements of the program could be stalled before they get off the ground.

Medicare drug price negotiations hit critical phase

Kinross Gold

Lockheed Martin

Within the dividend stock portfolio, there is a case for finer diversification. First, there are blue-chip dividend stocks with stable cash flows and relatively muted dividend growth.

The 3 Best Dividend Growth Stocks to Buy in January 2024

Amgen

Centene

Cencora Inc

Catalent

Medtronic

Moderna

Regeneron Pharmaceuticals

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.

Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use

More veterinary professionals are provided access to and are pursuing mental health resources for their overall wellbeing with continued improvements on the horizon RAHWAY, N.J. , Jan. 15, 2024 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J.

Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams

Allstate

Arista Networks

Intuitive Surgical

Eli Lilly

NVIDIA

Palo Alto Networks

The S&P 500 rebounded last week near record highs, but is up just 0.2% so far in 2024. These are the index's top performers so far.

These 9 Stocks Are Running To Start 2024

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in combination with chemoradiotherapy to treat newly diagnosed patients with a type of advanced cervical cancer.

Merck's Keytruda combo gets FDA nod for expanded use in cervical cancer

Sanofi

Teva Pharmaceutical

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

Broadcom

Exxon Mobil

Investing in the best blue-chip stocks offers some benefits, especially lower volatility. Typically, these stocks are stable companies with a lower beta than their peers.

The 3 Best Blue-Chip Stocks to Buy in January 2024

Harpoon Therapeutics Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Harpoon Therapeutics, Inc. (NasdaqCM: HARP) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Harpoon will receive $23.00 in cash for each share of Harpoon that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP

News for Merck Stock (MRK)